These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
75 related articles for article (PubMed ID: 11062207)
1. Impact of a new quinolone, DU-6859a, and two oral carbapenems, CS-834 and L-084, on the rat and mouse caecal microflora. Liu CX; Kato N; Watanabe K; Sakata T; Kaneko T J Antimicrob Chemother; 2000 Nov; 46(5):823-6. PubMed ID: 11062207 [TBL] [Abstract][Full Text] [Related]
2. In vitro activity of R-95867, the active metabolite of a new oral carbapenem, CS-834, against anaerobic bacteria. Kato N; Tanaka K; Kato H; Watanabe K J Antimicrob Chemother; 2000 Mar; 45(3):357-61. PubMed ID: 10702557 [TBL] [Abstract][Full Text] [Related]
3. Comparison of in vitro activities of DU-6859a and other fluoroquinolones against Japanese isolates of anaerobic bacteria. Kato N; Kato H; Tanaka-Bando K; Watanabe K; Ueno K Clin Infect Dis; 1996 Dec; 23 Suppl 1():S31-5. PubMed ID: 8953104 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic effects of a new quinolone, DU-6859a, on polymicrobial infections in a newly designed model of rat uterine endometritis. Mikamo H; Kawazoe K; Sato Y; Izumi K; Tamaya T J Antimicrob Chemother; 1998 Jan; 41(1):131-3. PubMed ID: 9511050 [TBL] [Abstract][Full Text] [Related]
5. Effect of lomefloxacin on the normal oral and intestinal microflora. Edlund C; Brismar B; Nord CE Eur J Clin Microbiol Infect Dis; 1990 Jan; 9(1):35-9. PubMed ID: 2303064 [TBL] [Abstract][Full Text] [Related]
6. In vitro activity of quinolones and other antimicrobial agents against anaerobic bacteria. Nord CE Clin Infect Dis; 1996 Dec; 23 Suppl 1():S15-8. PubMed ID: 8953101 [TBL] [Abstract][Full Text] [Related]
7. The effect of DU-6859a, a new potent fluoroquinolone, on fecal microflora in human volunteers. Inagaki Y; Yamamoto N; Chida T; Okamura N; Tanaka M Jpn J Antibiot; 1995 Mar; 48(3):368-79. PubMed ID: 7752450 [TBL] [Abstract][Full Text] [Related]
8. The in-vitro activity of tosufloxacin, a new fluorinated quinolone, compared with that of ciprofloxacin and temafloxacin. King A; Bethune L; Phillips I J Antimicrob Chemother; 1991 Nov; 28(5):719-25. PubMed ID: 1663930 [TBL] [Abstract][Full Text] [Related]
9. Effects of DU-6859a, a new quinolone antimicrobial, on theophylline metabolism in in vitro and in vivo studies. Niki Y; Itokawa K; Okazaki O Antimicrob Agents Chemother; 1998 Jul; 42(7):1751-5. PubMed ID: 9661016 [TBL] [Abstract][Full Text] [Related]
10. In-vitro comparison of DU-6859a, a novel fluoroquinolone, with other quinolones and oral cephalosporins tested against 5086 recent clinical isolates. Marshall SA; Jones RN; Murray PR; Washington JA; Allen SD; Gerlach EH; Erwin ME J Antimicrob Chemother; 1993 Dec; 32(6):877-84. PubMed ID: 8144428 [No Abstract] [Full Text] [Related]
11. Different effects of difructose anhydride III and inulin-type fructans on caecal microbiota in rats. Tamura A; Mita Y; Shigematsu N; Hara H; Nishimura N Arch Anim Nutr; 2006 Oct; 60(5):358-64. PubMed ID: 17036745 [TBL] [Abstract][Full Text] [Related]
12. Effects of erythromycin, flurithromycin and teicoplanin on rat microflora. Cuzzolin L; Fracasso ME; Leone R; Benoni G J Chemother; 1989 Jul; 1(4 Suppl):196-7. PubMed ID: 16312366 [No Abstract] [Full Text] [Related]
13. Comparative in-vitro and in-vivo activity of AM-1155 against anaerobic bacteria. Kato N; Kato H; Tanaka-Bandoh K; Watanabe K; Ueno K J Antimicrob Chemother; 1997 Nov; 40(5):631-7. PubMed ID: 9421310 [TBL] [Abstract][Full Text] [Related]
14. The effects of increasing levels of quinolone resistance on in-vitro activity of four quinolones. Thomson KS; Sanders CC J Antimicrob Chemother; 1998 Aug; 42(2):179-87. PubMed ID: 9738835 [TBL] [Abstract][Full Text] [Related]
15. Quinolone activity against anaerobes. Appelbaum PC Drugs; 1999; 58 Suppl 2():60-4. PubMed ID: 10553708 [TBL] [Abstract][Full Text] [Related]
16. Bactericidal activity of the new 4-quinolones DU-6859a and DV-7751a. Morrissey I; Smith JT J Med Microbiol; 1995 Jul; 43(1):4-8. PubMed ID: 7608954 [TBL] [Abstract][Full Text] [Related]
17. Comparison of gyrA and parC mutations and resistance levels among fluoroquinolone-resistant isolates and laboratory-derived mutants of oral streptococci. Kaneko A; Sasaki J; Shimadzu M; Kanayama A; Saika T; Kobayashi I J Antimicrob Chemother; 2000 Jun; 45(6):771-5. PubMed ID: 10837428 [TBL] [Abstract][Full Text] [Related]
18. Antimicrobial activity of a new fluoroquinolone, DU-6859a, against quinolone-resistant clinical isolates of Neisseria gonorrhoeae with genetic alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV. Deguchi T; Yasuda M; Nakano M; Kanematsu E; Ozeki S; Ishihara S; Saito I; Kawada Y J Antimicrob Chemother; 1997 Feb; 39(2):247-9. PubMed ID: 9069547 [TBL] [Abstract][Full Text] [Related]
19. [Transfer of the cecal flora of the hamster to the germfree C3H mouse: use of this model to study the flora of the anti-Clostridium difficile barrier]. Su WJ; Bourlioux P; Bournaud M; Besnier MO; Fourniat J Can J Microbiol; 1986 Feb; 32(2):132-6. PubMed ID: 3516351 [TBL] [Abstract][Full Text] [Related]
20. Effect of quinolones on intestinal ecology. Edlund C; Nord CE Drugs; 1999; 58 Suppl 2():65-70. PubMed ID: 10553709 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]